Fed up with a string of safety and quality problems, the U.S. Food and Drug Administration has launched a new wave of surprise inspections at compounding pharmacies.
Some recent problems with these pharmacies include glass particles found in generic versions of Lipitor, made by an Indian company called Ranbaxy.
Ranbaxy saw its share of the U.S. market decline sharply after it recalled certain lots of Lipitor, also known as atorvastatin, in November. The recall involved contamination with tiny glass particles.
Another compounding pharmacy nightmare was the spread of a dangerous strain of meningitis linked to tainted drugs.
Here's how a story in The Washington Post describes the new FDA inspection program:
"The actions are part of a new program aimed at the multibillion-dollar compounding industry that has fallen between the regulatory cracks. The inspections were the first targeted enforcement actions against large compounders since the FDA found filthy conditions at a Massachusetts pharmacy that shipped contaminated steroid shots to 23 states. The shots caused the outbreak that has so far killed 48 people and sickened 666 others, making it the country's worst drug disaster in several decades."
The steroid problems stemmed from quality control issues at the now-infamous New England Compounding Center. But the above article in the Post shows that those problems are not isolated, and that the lightly regulated pharmacy compounding industry is in fact riddled with safety issues.
If you or a loved one have been injured by a defective pharmaceutical product, including the Ranbaxy recall or the meningitis outbreak, call Attorney Alex Davis or send an email to email@example.com for a free consultation.